What role will proprotein convertase subtilisin/kexin type 9 inhibitors play in hyperlipidemia management?-Reference-Cited by-同舟云学术

What role will proprotein convertase subtilisin/kexin type 9 inhibitors play in hyperlipidemia management?

Published:2016-04 Issue:2 Volume:23 Page:97-105
ISSN:1752-296X
Container-title:Current Opinion in Endocrinology, Diabetes & Obesity
language:en
Short-container-title:

Author:

Stein Evan A.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Nutrition and Dietetics,Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference44 articles.

1. Lovastatin and beyond: the history of the HMG CoA reductase inhibitors.;Tobert;Nat Rev,2003

2. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).;Pedersen;Lancet,1994

3. for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia.;Shepherd;N Engl J Med,1995

4. for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels.;Sacks;N Engl J Med,1996

5. The lipid-lowering effects of atorvastatin, a new HMG-CoA reductase inhibitor: results of a randomized double-masked study.;Heinonen;Clin Therap,1996

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Population PK/PD modeling of low‐density lipoprotein cholesterol response in hypercholesterolemic participants following administration of bococizumab, a potent anti‐PCSK9 monoclonal antibody;CPT: Pharmacometrics & Systems Pharmacology;2023-11-22

2. Assessing the Potential Risk of Cross-Reactivity Between Anti-Bococizumab Antibodies and Other Anti-PCSK9 Monoclonal Antibodies;BioDrugs;2019-09-16

3. Comparative Pharmacokinetics and Pharmacodynamics of Bococizumab Following a Single Subcutaneous Injection Using Drug Substance Manufactured at Two Sites or Administration via Two Different Devices;Clinical Pharmacology in Drug Development;2018-04-24

4. Insights into a PCSK9 structural groove: a harbinger of new drugs to reduce LDL-cholesterol;Nature Structural & Molecular Biology;2017-10

5. Pharmacokinetics and pharmacodynamics of bococizumab, a monoclonal antibody to PCSK9, after single subcutaneous injection at three sites [NCT 02043301];Cardiovascular Therapeutics;2017-09-14